Remicade Phase III psoriasis data

Remicade infliximab from Johnson & Johnson (JNJ) and Schering-Plough (SGP) met the primary endpoint of PASI 75 at week 10 in the Phase III EXPRESS II trial to treat moderate to severe plaque psoriasis...